Your browser doesn't support javascript.
loading
Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives.
Abou Dalle, Iman; Dulery, Remy; Moukalled, Nour; Ricard, Laure; Stocker, Nicolas; El-Cheikh, Jean; Mohty, Mohamad; Bazarbachi, Ali.
Afiliação
  • Abou Dalle I; Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon.
  • Dulery R; Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
  • Moukalled N; Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon.
  • Ricard L; Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
  • Stocker N; Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
  • El-Cheikh J; Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon.
  • Mohty M; Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
  • Bazarbachi A; Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon. bazarbac@aub.edu.lb.
Blood Cancer J ; 14(1): 23, 2024 01 25.
Article em En | MEDLINE | ID: mdl-38272863
ABSTRACT
Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Linfoma de Células B / Transplante de Células-Tronco Hematopoéticas Limite: Humans Idioma: En Revista: Blood Cancer J Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Líbano
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Linfoma de Células B / Transplante de Células-Tronco Hematopoéticas Limite: Humans Idioma: En Revista: Blood Cancer J Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Líbano